Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mavacamten in Adults with Symptomatic Nonobstructive Hypertrophic Cardiomyopathy
2021-005329-26Phase 3Active
- Sponsor
- MyoKardia
- Start
- Oct 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in hypertrophic cardiomyopathy (HCM) comparing Mavacamten with Placebo (2 arms). Primary endpoint: Change from baseline in KCCQ Clinical Summary Score. Started Oct 2022; status: active.
02
Drugs
mavacamten
03
Conditions
hypertrophic cardiomyopathy (HCM)
Beyond the preview
Go deeper on 2021-005329-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-005329-26.